Commercial Development and Patient Benefit of Adoptive Cell Therapy (ACT) for Cancer

Impact: Technological impacts, Health and wellbeing, Economic, Policy


Immunotherapy is revolutionising cancer treatment. University of Manchester (UoM) researchers have been at the forefront of developing a branch of immune-oncology, Adoptive Cell Therapy (ACT), through molecular and pre-clinical research to delivery within the NHS as standard-of-care treatment. Development and commercialisation of ACT products has led to economic impact, with the UoM spin-out company Immetacyte expanding from 40 employees in 2019 to merger with Instil Bio in 2020 (raising USD172,000,000 in financing). Worldwide, thousands of patients have now benefited from these life-saving treatments and in the UK alone, around 200 patients per year currently receive commercial products.
Impact date1 Aug 201331 Jul 2020
Category of impactTechnological impacts, Health and wellbeing, Economic, Policy
Impact levelAdoption

Research Beacons, Institutes and Platforms

  • Cancer